• Explore /
  • Poster
  • / Fibroblast growth factor receptor 3 (<em>FGFR3</em>) alterations in PROOF 302: A phase III trial of infigratinib (BGJ398) as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC).

Fibroblast growth factor receptor 3 (FGFR3) alterations in PROOF 302: A phase III trial of infigratinib (BGJ398) as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC).

Abstract Video & Slides Poster

Authors

null

Petros Grivas

Division of Oncology, Department of Medicine, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA

Petros Grivas , Siamak Daneshmand , Vladimir Makarov , Joaquim Bellmunt , Srikala S. Sridhar , Guru P. Sonpavde , Suzanne Cole , Abhishek Tripathi , Bishoy Morris Faltas , Seth P. Lerner , Mark T. Fleming , Yohann Loriot , Joshua J Meeks , Viraj A. Master , Kimberlee Davis , David Friedrich Van Veenhuyzen , Shugufa Afifi , Sumanta Kumar Pal , Shilpa Gupta

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Local-Regional Disease

Clinical Trial Registration Number

NCT04197986

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4511)

DOI

10.1200/JCO.2023.41.16_suppl.4511

Abstract #

4511

Poster Bd #

3

Abstract Disclosures

Similar Posters

First Author: Siamak Daneshmand

First Author: Suzanne Cole

First Author: Sumanta K. Pal

First Author: Maria Pagano